In the originally published article there was an error in Table 1. The reduction in monthly migraine days over 12 weeks versus placebo with quarterly fremanezumab was incorrectly given as “-0.6”; this should read “-3.7”.
Erratum to: Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Select a Section…
1
Article
2
Further Resources
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The surge in social media use seems to have become a sign of our times. Social media has ramified into not only our personal lives but, importantly, also our professional lives and will continue to do so in the future.1–4 At the same time, more neurologists resorted to online learning modalities, including podcasts and social media […]
Mark CompleteCompleted
BookmarkBookmarked
Photophobia is a complex disorder that can involve aversion not simply to bright light but to spatial patterns, colour and flicker.1 It is common in neurological diseases that involve the visual system,2 of which migraine is the most prevalent. Tinted ...
Mark CompleteCompleted
BookmarkBookmarked
Neuromodulation is a recent technique that has increasingly been used for the abortive and preventive treatment of migraine and other primary headache disorders.1 It has previously been found to be helpful in the treatment of other neurological illnesses, such as ...
Mark CompleteCompleted
BookmarkBookmarked
For a condition as highly prevalent and debilitating as migraine, there is still too little awareness of it and the impact it has. There is little understanding of the different symptoms and stages of a migraine attack, the frequency with ...
Mark CompleteCompleted
BookmarkBookmarked
Migraine is a common and disabling condition with substantial health and socioeconomic implications. Approximately 1.04 billion people worldwide have migraine disease.1 The condition disproportionately affects women, with 19% of women versus 10% of men reporting a history of migraine.1 Migraine is the second ...
Mark CompleteCompleted
BookmarkBookmarked
It cannot be seen, cannot be felt, cannot be heard, cannot be smelt. It lies behind stars and under hills, and empty holes it fills. It comes first and follows after, ends life, kills laughter. The Hobbit. JRR Tolkien ‘Darkness’ ...
Mark CompleteCompleted
BookmarkBookmarked
Migraine is a neurologic disease characterized by recurrent attacks of head pain and symptoms such as nausea, photophobia and phonophobia, which last hours to days.1 Attacks themselves can be disabling, and due to the often unpredictable and unavoidable nature of ...
Mark CompleteCompleted
BookmarkBookmarked
A university lecturer first experienced headaches during the summer of 1989, when he was aged 26 years. The headache periods initially lasted about 1 day and because the pain was in the trigeminal area both an optometrist and a dentist were consulted. The ...
Mark CompleteCompleted
BookmarkBookmarked
Treatment guidelines recommend preventive therapy for migraine, based primarily on the frequency of migraine attacks.1 Migraine-related burden of disease increases with the number of headache days; however, even fewer than 4 headache days per month can result in severe disability in ...
Mark CompleteCompleted
BookmarkBookmarked
Migraine is one of the most prevalent and disabling diseases worldwide, affecting more than one billion people in 2016.1 It is characterized by recurrent headache attacks with nausea/vomiting, photophobia and phonophobia.2 Currently, the first line of acute treatment of migraine ...
Mark CompleteCompleted
BookmarkBookmarked
In 2018, the Global Burden of Disease study placed headache disorders as the second leading cause of years lived with disability.1 As another indicator of its burden, headache was ranked among the leading causes of years lived with disability.1 Given its ...
Mark CompleteCompleted
BookmarkBookmarked
Despite the fact that migraine is the most prevalent neurological disorder worldwide, it remains under-diagnosed and under-treated in more than half of all patients.1 In the past decade, the development of monoclonal antibodies capable of blocking either calcitonin gene-related peptide (...
Mark CompleteCompleted
BookmarkBookmarked
Treatment of acute central nervous system (CNS) conditions requires effective drugs that can provide rapid onset of effect, consistent blood levels, ease-of-use for patient or caregiver, and acceptable tolerability. Solid oral dosage forms account for up to 75% of prescriptions from ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
